Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 19, 2021

View Archived Issues

Phase II data reported for cabozantinib in type I neurofibromatosis with PNs

BET inhibitors synergize with BCL-2 or HDAC inhibitors in Waldenstrom macroglobulinemia

Grifols to begin clinical evaluation of new COVID-19 treatment

Biohaven presents focused analysis data from phase II/III study of troriluzole in AD

First patient dosed in phase II study of alisporivir in early-stage COVID-19

Eli Lilly initiates phase II study of LY-3462817 in rheumatoid arthritis

Enrollment opens in phase II study of vactosertib plus pembrolizumab in NSCLC

Murine model of SARS-CoV-2 infection developed via mRNA transfection of hACE2

Sobetirome and its prodrug show efficacy in models of EAE

LCP2 is a therapeutic target in lethal sepsis

Shanghai Institute of Materia Medica dicloses new hepatitis B virus inhibitors

New CDK9/cyclin T1 inhibitors discovered at Medshine Discovery

Preclinical data show SENS-401 reduces loss of residual hearing after cochlear implantation

Hangzhou Hertz Pharmaceutical patents casein kinase 1 isoform epsilon inhibitors

DMC recommends start of part 2 of COVA study of Sarconeos in COVID-19

Guangdong Newopp Biopharmaceuticals identifies mutant KRAS inhibitors

New JAK inhibitors synthesized at Guangzhou Innocare Pharma Tech

Phase I trial of LY-CovMab in China completes enrollment

Novel GPC3/CD47 bispecific antibody shows strong antitumor activity in HCC xenografts

HELP is on its way for herpetic stromal keratitis

Transgene gains clearance in France for phase I/IIa study of BT-001 for solid tumors

CRY1 unveiled as a hormone-induced tumorigenic factor in prostate cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...